Praluzatamab ravtansine
Based on 1 Customer Validation
Praluzatamab ravtansine (CX-2009) is an anti-CD166 antibody drug conjugate (ADC) with an Kd value of 25.15 nM. Praluzatamab ravtansine contains an anti-CD166 monoclonal antibody Praluzatamab (HY-P99788) conjugated to the microtubule inhibitor DM4 (HY-12454). Praluzatamab ravtansine shows tumor targeting and can be used for the study of lung cancer and breast cancer.
For research use only. We do not sell to patients.
- Purity: 99.07%
- CAS No.: 2145115-85-9
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
CD166[1]
Praluzatamab ravtansine (110 µg and 510 µg; i.v.; single dose) is activated in tumor tissue of H292 xenotransplantation mice[2].
Praluzatamab ravtansine (5 mg/kg; i.v.; single dose on day 0 and 7) significantly reduces tumor volume in H292 xenograft tumor-bearing mice model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:H292 xenograft tumor-bearing mice model[2].
-
Dosage:110 µg, 510 µg or 5 mg/kg.
-
Administration:Intravenous injection; single dose.
-
Result:Had tumor targeting, activated by tumor tissue and reduced tumor volume.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2145115-85-9
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Praluzatamab ravtansine]
-
Synonyms
CX-2009; CD166
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Purity & Documentation
-
Data Sheet (267 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Boni V, et al. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 May 13;28(10):2020-2029. [Content Brief]
[2]. Chomet M, et al. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice. Theranostics. 2020 Apr 27;10(13):5815-5828. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Praluzatamab ravtansine Related Classifications
HY-P99789 Related Classifications
Powered by Bioz